Law360, Bloomberg Law, the New York Law Journal, Thomson Reuters Westlaw Today, Global Legal Chronicle and Life Sciences Intellectual Property Review were among the media outlets that covered the arrival of McGuireWoods partner Craig Bleifer, a nationally recognized healthcare and life sciences attorney who joined the firm in New York.
Bleifer has more than three decades of experience in pharmaceutical and healthcare law, including 20 years as in-house counsel at leading pharma companies Novo Nordisk and Daiichi Sankyo. He counsels clients on legal, compliance, policy and regulatory matters involving healthcare products and businesses at all stages. He advises on clinical studies, inspections and recalls and drug safety programs and assists clients in product labeling negotiations with the U.S. Food and Drug Administration.
Bleifer told Law360 that McGuireWoods has taken significant steps to strengthen its life sciences capabilities, particularly for clients in FDA-regulated industries.
“The really attractive thing about McGuireWoods is that they’ve had an FDA practice, but they’re really reinvigorating it and committed to growing it and providing really great offerings to both the pharma and medical device companies,” as well as the private equity and venture capital firms that invest in those entities, Bleifer said in Law360’s Nov. 19, 2024, story.